Biotech entity
Of the tracked stories, 2 of 4 also mention Food and Drug Administration, the most common co-covered peer. Each story carries 5.8 original sources on average, compared with 3.5 for the broader beat in this window. At 7.5, the average consequence score sits above the same-window beat average of 6.2.
Last mentioned: Jul 14, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 4 also mention Food and Drug Administration, the most common co-covered peer. Each story carries 5.8 original sources on average, compared with 3.5 for the broader beat in this window. At 7.5, the average consequence score sits above the same-window beat average of 6.2. The 157-day window averages about 0.2 stories each week. Coverage clusters in funding, which accounts for 2 of those 4, with the remainder spread across 2 other categories. We currently track 4 Biotech stories that mention White House, published between March 16, 2026 and August 19, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 462 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering White House. Shared-story counts are live from our verified record — not editorial picks.
Hartford Courant reports Trump picks Overton
The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
Market Impact
Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
Refusal to File
Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
Grants Rescinded
The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
Workaround Supported
FDA officials appear to support Moderna's plan to use data from a smaller trial as a workaround for control group concerns.
Collaboration Begins
Moderna starts working with the FDA on the design for its mRNA flu vaccine trials.
Biotech and pharma investors and executives face a potentially new FDA commissioner with no public drug-review track record. If Dr. Heidi Overton is confirmed, her priorities could reshape clinical trial standards, accelerated approval pathways, and review timelines. Early signals from the White House and confirmation hearings will matter most.
Source: abc7news.com · STAT News
The Trump administration's use of keyword filters to cancel nearly $2 billion in UC research grants dealt a heavy blow to biomedical innovation, affecting studies from gene therapy to clinical trials. The legal admission exposes the unscientific basis for the terminations.
The $1.4 billion Ebola component of the White House’s war funding request could accelerate development of new vaccines and antivirals, offering a rare bright spot for biopharma firms amid broader fiscal uncertainty.
Source: stcatharinesstandard.ca · yahoo.com
Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
White House is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
